Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoimmunotherapy + Pembrolizumab in Cutaneous Metastatic Breast Cancer
NCT03982004Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in breast cancer, sponsored by Washington University School of Medicine. Primary endpoint: Rate of treatment emergent grade 3 or higher toxicities. Started Sep 2020; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03982004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982004.